NEWS & EVENTS

– Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome – BASEL, Switzerland, Oct. 30, 2024 – Noema ...

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the ...

Top-line results from Phase 2B study expected in first quarter of 2025 BASEL, Switzerland, August 13, 2024 – Noema Pharma AG, a clinical-stage biotech company targeting ...

NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms ...

BASEL, Switzerland, January 3, 2024 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of management ...

— Appointment supports Noema’s robust clinical-stage pipeline addressing high value CNS disorders — BASEL, Switzerland, November 15, 2023 — Noema Pharma, a clinical-stage biotech company ...

Company is well-positioned to advance robust clinical-stage CNS pipeline, following oversubscribed Series B financing earlier this year BASEL, Switzerland, June 21, 2023 – Noema Pharma, ...

BASEL, Switzerland, May 9, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of ...

Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders Nanna Lüneborg, General Partner at Forbion and Rachel Mears, ...

BASEL, Switzerland and BOSTON, Massachusetts, January 5, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members ...

BASEL, Switzerland, October 18, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food ...

Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgia LIBRATN (NOE-101 Phase 2/3 ...

Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 ...

Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, ...

BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive ...

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical ...

Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 14, 2022 – Noema Pharma, a Swiss-based clinical ...

BASEL, Switzerland, December 8, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will ...

BASEL, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...

BASEL, Switzerland, October 4, 2021 –Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of ...

BASEL, Switzerland, September 2, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend ...

First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, ...

BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion ...

BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend ...